Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole

Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We investigated the in vitro and in vivo preclinical activity of KW-2450 plus lapatinib and letrozole and conducted a phase I trial of the triple-drug combination in one male and 10...

Full description

Bibliographic Details
Main Authors: Hiroshi Umehara, Yoshimi Maekawa, Fumito Koizumi, Makiko Shimizu, Toshio Ota, Tamer M. Fouad, Jie Willey, Hidekuni Kaito, Norihiko Shiraishi, Daisuke Nakashima, Shiro Akinaga, Naoto T. Ueno
Format: Article
Language:English
Published: SAGE Publishing 2018-07-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/1758835918786858

Internet

https://doi.org/10.1177/1758835918786858

Similar Items